Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0001924,
umls-concept:C0017262,
umls-concept:C0021920,
umls-concept:C0025936,
umls-concept:C0026131,
umls-concept:C0185117,
umls-concept:C0205369,
umls-concept:C0304925,
umls-concept:C0376702,
umls-concept:C0439851,
umls-concept:C0441889,
umls-concept:C0453882,
umls-concept:C1552596,
umls-concept:C1947931,
umls-concept:C2911684
|
| pubmed:issue |
6
|
| pubmed:dateCreated |
1995-1-20
|
| pubmed:abstractText |
A new series of expression vectors, each comprised of the beta-lactoglobulin (BLG) promoter driving one of a variety of human serum albumin (HSA) minigenes or the entire gene, were evaluated for their ability to direct expression of HSA in vitro in COS tissue culture cells and into the milk of transgenic mice. Vectors directed a hierarchy of expression levels in vitro, dependent upon the specific complement of HSA introns included. HSA introns acted in a synergistic manner. In addition, minigenes comprised of specific subsets of introns were more efficacious than the entire HSA gene with all of its introns. Transgenic mice expressed as much as 10 mg ml-1 of HSA in their milk. Vectors comprised of specific intron subsets directed levels at 1 mg ml-1 or greater in the milk of 20% of generated transgenics. A statistical correlation between the expression level trend in vitro with the trend of expression in vivo (% which express) at detectable levels (p = 0.0015) and at the level of greater than 0.1 mg ml-1 (p = 0.0156) was demonstrated. A weak correlation existed (p = 0.0526) at in vivo levels of 1 mg ml-1 or greater. These new vectors are expected to direct the production of high levels of HSA in the milk of a large percentage of generated transgenic dairy animals.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0962-8819
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
3
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
365-75
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:8000433-Animals,
pubmed-meshheading:8000433-Cell Line,
pubmed-meshheading:8000433-Cloning, Molecular,
pubmed-meshheading:8000433-Female,
pubmed-meshheading:8000433-Gene Expression Regulation,
pubmed-meshheading:8000433-Genetic Vectors,
pubmed-meshheading:8000433-Humans,
pubmed-meshheading:8000433-Introns,
pubmed-meshheading:8000433-Kidney,
pubmed-meshheading:8000433-Lactation,
pubmed-meshheading:8000433-Lactoglobulins,
pubmed-meshheading:8000433-Mice,
pubmed-meshheading:8000433-Mice, Transgenic,
pubmed-meshheading:8000433-Milk,
pubmed-meshheading:8000433-Promoter Regions, Genetic,
pubmed-meshheading:8000433-Recombinant Fusion Proteins,
pubmed-meshheading:8000433-Serum Albumin,
pubmed-meshheading:8000433-Transfection
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
Specific combinations of human serum albumin introns direct high level expression of albumin in transfected COS cells and in the milk of transgenic mice.
|
| pubmed:affiliation |
Rhône-Poulenc Rorer Central Research, Collegeville, PA 19426.
|
| pubmed:publicationType |
Journal Article
|